Key result
Novel ACE2 activator H4 and prodrug enhance ACE2 activity and reduce lung inflammation in bacterial pneumonia.
Why the study?
ACE2 can optimize inflammatory responses, but clinical applicability has been limited by a lack of dependable ACE2 activators.
Does the novel ACE2 activator H4 or its prodrug reduce bacterial infection-induced lung inflammation in preclinical models?
Does the novel ACE2 activator H4 or its prodrug reduce bacterial infection-induced lung inflammation in preclinical models?
H4 and its prodrug represent a promising novel class of specific ACE2 activators for the treatment and prevention of acute inflammatory lung diseases.
Answers are grounded in this paper and cite their sources.
May support ACE2 activator development for lung inflammation; hypothesis-generating and should not yet change practice.
Exacerbated inflammatory responses can be detrimental and pose fatal threats to the host, as exemplified by the global impact of the COVID-19 pandemic, resulting in millions of fatalities. Developing novel drugs to combat the damaging effects of inflammation is essential for both preventive measures and therapeutic interventions. Accumulating evidence suggests that Angiotensin Converting Enzyme 2 (ACE2) possesses the ability to optimize inflammatory responses. However, the clinical applicability of this potential is limited due to the lack of dependable ACE2 activators. In this study, we conducted a screening of an FDA-approved drug library and successfully identified a novel ACE2 activator, termed H4. The activator demonstrated the capability to mitigate lung inflammation caused by bacterial lung infections, effectively modulating neutrophil infiltration. Importantly, to improve the clinical applicability of the poorly water-soluble H4, we developed a prodrug variant with significantly enhanced water solubility while maintaining a similar level of efficacy as H4 in attenuating inflammatory responses in the lungs of mice exposed to bacterial infections. This finding highlights the potential of formulated H4 as a promising candidate for the treatment and prevention of inflammatory diseases, including lung-related conditions.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2023) studied Bacterial infection-induced lung inflammation. H4 and its prodrug variant vs. Saline or vehicle control was evaluated on ACE2 activity, lung inflammation, and neutrophil infiltration. H4 and its water-soluble prodrug significantly enhanced ACE2 activity and mitigated lung inflammation, including neutrophil infiltration, in mice with Pseudomonas aeruginosa-induced bacterial pneumonia.
Synapse has enriched 10 related papers. Consider them for comparative context: